Increased levels of immune transcript in patients with acute GVHD after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 31, Issue 3, 2003, Pages 183-190

  Jaksch, M ^a   Uzunel, M ^a   Martinez Cangana, G ^a   Remberger, M ^a   Mattsson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

GVHD; Quantitative RT PCR; SCT

Indexed keywords

BUSULFAN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FAS ANTIGEN; FAS LIGAND; GRANZYME B; MESSENGER RNA; METHOTREXATE; METHYLPREDNISOLONE; PERFORIN; RNA; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; DISEASE SEVERITY; DONOR; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; MALE; PATIENT MONITORING; PERIPHERAL CIRCULATION; PHYSICIAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

ACUTE DISEASE; ADULT; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; GRANZYMES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037294809     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703807     Document Type: Article

References (38)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
2. Ringden O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JML, Deeg HJ, Burakoff SJ (eds). Graft vs Host Disease. Marcel Dekker, Inc.: New York, 1996, pp 525-529.
3. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985; 88: 215-238.
4. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds). Graft-vs-Host Disease. Marcel Dekker: New York, 1997, pp 257-289.
5. Korngold R, Sprent J. T-cell subsets in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K (eds). Graft-vs.-Host Disease. Marcel Dekker: New York, 1990, pp 31-49.
6. Kagi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
7. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652.
8. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
9. Berke G. The CTL's kiss of death. Cell 1995; 81: 9-12.
10. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4T cell killing of target cells. J Immunol 1998; 161: 2195-2200.
11. Via CS, Nguyen P, Shustov A et al. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996; 157: 5387-5393.
12. Braun MY, Lowin B, French L et al. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657-661.
13. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/ granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100: 904-911.
14. Hattori K, Hirano T, Miyajima H et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051-4055.
15. Lee S, Chong SY, Lee JW et al. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Bone Marrow Transplant 1997; 20: 883-888.
16. Das H, Imoto S, Murayama T et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol 1999; 104: 795-800.
17. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
18. Snover DC. The pathology of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K (eds). Graft-vs.-Host Disease. Marcel Dekker: New York, 1990, pp 337-353.
19. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
20. Kanda Y, Tanaka Y, Shirakawa K et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998; 22: 751-754.
21. Remberger M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99-104.
22. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455-464.
23. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
24. Remberger M, Svahn BM, Hentschke P et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-830.
25. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
26. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransp.ant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391-397.
27. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
28. Ringden O, Remberger M, Carlens S et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998; 66: 620-625.
29. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601-607.
30. Strehlau J, Pavlakis M, Lipman M et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700.
31. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
32. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645-2656.
33. Hattori K, Hirano T, Ushiyama C et al. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood 1997; 90: 542-548.
34. Snover DC, Weisdorf SA, Ramsay NK et al. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 1984; 4: 123-130.
35. Schwaighofer H, Herold M, Schwarz T et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994; 58: 430-436.
36. Remberger M, Ringden O. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. Eur J Haematol 1997; 59: 254-262.
37. Holler E, Ferrara JLM. Antagonists of inflammatory cytokines: prophylactic and therapeutic applications. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds). Graft-vs.-Host Disease. Marcel Dekker: New York, 1997, pp 667-692.
38. Kami M, Matsumura T, Tanaka Y et al. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leukemia Lymphoma 2000; 38: 533-540.